Tech Center 1700 • Art Units: 1641 1677 1678 1758 1787
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17851215 | IMMUNOCHROMATOGRAPHY | Non-Final OA | FUJIFILM Corporation |
| 17904873 | SYSTEMS AND METHODS FOR DETECTION OF ANALYTES | Non-Final OA | The Texas A&M University System |
| 18096464 | METHODS OF ASSESSING RISK OF AND TREATING PREECLAMPSIA AND SUBTYPES THEREOF | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18557941 | Biomarkers for Neurodegenerative Disease | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 18279624 | BIOMARKER | Non-Final OA | Oxford University Innovation Limited |
| 18474826 | BIOMARKERS AND METHODS FOR DIFFERENTIATING BETWEEN MILD AND SUPERMILD TRAUMATIC BRAIN INJURY | Non-Final OA | Abbott Laboratories |
| 18157250 | METHOD OF ASSISTING DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE | Non-Final OA | OSAKA UNIVERSITY |
| 17595478 | REAGENTS FOR SANDWICH IMMUNOASSAYS USING PARTICLE ENHANCED AGGLUTINATION DETECTION AND METHODS OF PRODUCTION AND USE THEREOF | Final Rejection | Siemens Healthcare Diagnostics Inc. |
| 18158768 | Biomarkers for identifying e-cigarette, or vaping, product use-associated lung injury | Non-Final OA | University of Rochester |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 17821951 | TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION | Final Rejection | Roche Diagnostics Operations, Inc. |
| 17772959 | SEPSIS MANAGEMENT | Non-Final OA | ROCHE DIAGNOSTICS OPERATIONS, INC. |
| 18276218 | MARKER FOR DIAGNOSIS OF NONALCOHOLIC FATTY LIVER DISEASE | Non-Final OA | BREXOGEN INC. |
| 17773896 | METHODS AND KITS FOR QUANTITATING RADIATION EXPOSURE | Non-Final OA | MESO SCALE TECHNOLOGIES, LLC. |
| 18257697 | USE OF ALARMINS AS BIOMARKERS FOR ASSESSING ISCHEMIA-REPERFUSION INJURY SEVERITY AFTER SOLID ORGAN TRANSPLANTATION | Non-Final OA | UNIVERSITE DE POITIERS |
| 17802290 | ANTIGEN FOR 2019 NOVEL CORONAVIRUS AND DETECTION USE THEREOF | Non-Final OA | XIAMEN UNIVERSITY |
| 18164679 | METHOD OF DETECTING TB IN BLOOD SAMPLE | Non-Final OA | The Administrators of the Tulane Educational Fund |
| 17789823 | METHODS FOR DETECTION OF PATHOGENIC ANTIPHOSPHOLIPID ANTIBODIES AND FOR IDENTIFICATION OF INHIBITORS | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 17602757 | A METHOD FOR DETERMINING THE LIKELIHOOD OF A PATIENT BEING RESPONSIVE TO CANCER IMMUNOTHERAPY | Non-Final OA | UNIVERSITÄT ZÜRICH |
| 18551454 | DIAGNOSIS OF ALZHEIMER'S DISEASE BY DETECTING AUTO-ANTIBODIES AGAINST Y-BOX BINDING PROTEIN-1 (YB-1) | Non-Final OA | CELLTREND GMBH |
| 18243034 | RAPID QUANTITATIVE ASSAY TO ASSESS DURATION OF INFECTION | Non-Final OA | SEDIA BIOSCIENCES CORPORATION |
| 18033222 | METHODS FOR IDENTIFYING AND TREATING ANTIBODY-MEDIATED ACQUIRED PRIMARY OR RECURRENT IDIOPATHIC NEPHROTIC SYNDROME | Non-Final OA | Boston Medical Center Corporation |
| 17735555 | COMPOSITIONS AND METHODS FOR THE DETECTION OF HOST CELL PROTEINS | Final Rejection | LONZA LTD. |
| 18261392 | METHOD FOR THE DETECTION OF LUNG CANCER | Non-Final OA | Belgian Volition SRL (GB/GB) |
| 18155299 | Methods for Middle Down Antibody Characterization | Non-Final OA | Universiteit Utrecht Holding B.V. |
| 18256453 | USE OF THE EMM ANTIGEN AS A BIOMARKER OF INHERITED GPI DEFICIENCIES | Non-Final OA | ETABLISSEMENT FRAN¿AIS DU SANG (EFS) |
| 18194151 | Pregnancy clock proteins for predicting due date and time to birth | Final Rejection | Sera Prognostics, Inc. |
| 18016384 | METHOD FOR DETERMINING WHETHER A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENT IS UNDERGOING A PRE-FLARE EVENT | Non-Final OA | Oklahoma Medical Research Foundation |
| 18111613 | MEASURING TRAIL BY LATERAL FLOW IMMUNOASSAY | Final Rejection | MeMed Diagnostics Ltd. |
| 18018121 | NOVEL CANCER BIOMARKER IN PANCREATIC CANCER OR MALIGNANT INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM | Non-Final OA | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy